Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes
MPR,
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion.
Even during a pandemic, the AHA says, research on obesity, hypertension, diabetes, and more continues to pay dividends.
American Heart Association While COVID-19 vaccines and variants continued to capture health headlines, a number of significant…